Joint research agreement
RNS & Investor News
SkinBioTherapeutics plc shareholding
19 May 2021
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its entire shareholding in SkinBioTherapeutics plc (AIM: SBTX) consisting of 36,138,569 ordinary shares representing 23.1% of SkinBioTherapeutics plc's total issued share capital, has been dematerialised and transferred to a nominee CREST account (Dowgate Wealth). OptiBiotix plc remains the beneficial owner of the transferred 36,138,569 ordinary shares.
There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 36,138,569 representing 23.1% of SkinBioTherapeutics plc's total issued share capital.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc
Neil Davidson, Chairman
Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD)
Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker)
Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020